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Abstract 
The clinical relevance of circadian rhythm modifications in patients on chemotherapy is unknown. Even so, 
circadian parameter I<O before chemotherapy independently predicted overall survival. This study 
investigates the relevance of I<O measured during chemotherapy for survival and symptoms. The circadian 
rest-activity pattern was monitored for 3 days using a wristwatch actigraph while 77 patients were 
receiving a chemotherapy course within an international randomized Phase III trial. Treatment consisted of 
first-line chronomodulated or conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin for 
metastatic colorectal cancer. I<O was computed as the percentage of minutes of activity counts in bed 
which were below the median of activity out of bed. Circadian disruption was defined by I<O equal to or 
less than 97.5%. Circadian disruption occurred in 39 patients (51%) on chemotherapy. It was associated 
with a significantly shorter overall survival, independently of other prognostic factors (multivariate Hazard 
Ratio: 2.12; p = 0.004). The median survival of patients with a robust circadian rhythm was 22.3 months as 
compared to 14.7 months in those with circadian disruption during chemotherapy. No toxicity was 
significantly associated with circadian disruption, but the incidence of grade ≥2 fatigue and of body weight 
loss ≥5% was two and threefold higher, respectively, in patients with disrupted circadian rhythm on 
chemotherapy. Chemotherapy disrupted circadian activity rhythm in nearly 50% of the patients. Circadian 
disruption on chemotherapy predicted for shorter overall survival. The prevention of chemotherapy-
induced circadian disruption might reduce toxicity and improve efficacy in cancer patients. 
Introduction 
Modern chemotherapy protocols have lead to an improvement in the survival of patients with metastatic 
colorectal cancer.1 However, these regimens also produce substantial systemic and organ-related 
toxicities, with a negative impact on patients' wellbeing.2 In particular, chemotherapy-induced fatigue and 
anorexia are frequent and bothersome complaints of cancer patients undergoing anticancer treatment, for 
which available pharmacological treatment is usually not very effective.3–5 These symptoms cluster 
frequently in cancer patients, with a possible immuno-neuroendocrine mechanism underlying their 
pathogenesis.6–9 The scientific evidence supporting this mechanism suggests that a disruption of the 
circadian timing system could be implicated.3, 10, 11 
The circadian timing system is hierarchically organized so as to rhythmically control several psychological 
and physiological functions, at physiological, cellular and molecular levels, over the 24 hr.12 This is the basis 
for studies of the administration of anticancer agents at defined times along the 24 hr, so-called 
chronotherapy.13, 14 The tight circadian coordination of biological functions from cells to whole organism 
plays an important role in cancer progression.14 A severe disruption of the circadian timing system through 
ablation of the hypothalamic pacemaker, or iterative alterations of the day–night cycle or clock gene 
mutations were found to accelerate experimental cancer progression.15–17 Conversely, enhancement of 
circadian coordination through regular meal timing slowed down experimental cancer growth.13, 14, 16, 18 
The circadian timing system of cancer patients can be evaluated through noninvasive monitoring of the 
rest-activity pattern using a wristwatch actimetry device.19, 20 The rest-activity rhythm is a validated 
biomarker of the circadian pacemaker in the hypothalamus both in experimental models and in humans.21 
Although the proper use of circadian should be reserved for studies performed in constant conditions, we 
use here the term circadian for daily rhythms also measured under environmental entraining cues. The 
rest-activity records gathered by the wristwatch actimetry device allow the computation of the relative 
amount of activity in-bed versus out-of-bed (I<O). This parameter was identified as a quantitative and 
clinically relevant circadian estimate in three cohorts involving a total of 436 patients with metastatic 
colorectal cancer, whose rest-activity pattern was monitored before receiving a new chemotherapy 
protocol.22–24 Median survival was nearly twice as high in patients with metastatic colorectal cancer 
whose baseline I<O exceeded 97.5% as compared to those with a lower I<O before chemotherapy 
delivery.22, 24 Several studies have also reported a significant association between fatigue, anorexia or 
weight loss and altered circadian function in cancer patients.3, 22, 24–28 
Chemotherapy has been found to disrupt circadian rhythms in rest-activity, core body temperature, 
corticosterone secretion and clock gene mRNA transcription as a function of dose and circadian timing in 
mice or rats.14, 29, 30 However, neither the occurrence of circadian disruption during chemotherapy nor 
its correlation with toxicity and survival have been systematically assessed in cancer patients. Here, we 
used data from a prospective companion study to an international randomized Phase III trial (EORTC05963) 
to carry out exploratory transversal and longitudinal analyses. The trial involved patients receiving first-line 
chemotherapy for metastatic colorectal cancer. The aim of this study was to investigate the impact of 
chemotherapy-induced circadian disruption on survival, and to identify the toxic symptoms associated with 
such disruption, in patients undergoing chemotherapy for metastatic colorectal cancer. 
Patients and Methods 
Study population 
This is a secondary analysis of prospectively collected data within an international, randomized, controlled 
open Phase III trial, EORTC 05963.31 In this trial, 564 patients with previously untreated metastatic 
colorectal cancer were enrolled at 36 Institutions, from October 1998 to February 2002. After signing an 
informed consent, patients were randomized to receive either a 4-day chronomodulated (chronoFLO4) or a 
2-day conventional (FOLFOX2) delivery schedule of oxaliplatin, folinic acid and 5-fluorouracil. The trial was 
approved by the ethics committee in each centre and/or country and was conducted in accordance with 
the Helsinki declaration.31 A subset of patients on this study at nine Institutions (four countries) 
participated in a prospective companion translational study involving rest-activity monitoring.24 Data from 
these patients were used for the current study. Here we report, for the first time, the correlation between 
the circadian rest-activity pattern evaluated during and immediately after chemotherapy delivery with 
efficacy outcomes and toxicity. 
Patients had their rest-activity pattern monitored with a wrist actimetry device within 7 days from the start 
of a chemotherapy course, with corresponding toxicity data for the same treatment course documented. 
When multiple rest-activity time series were available for the same patient, only the first one was used. A 
recent publication, further reported a transient alteration in circadian rest/activity rhythm during the first 
week of chemotherapy, with subsequent recovery.32, 33 On the basis of these reports, we limited our 
analysis to the data obtained during the first week following chemotherapy administration. 
Circadian rest/activity rhythm assessment 
Individual locomotor activity was monitored noninvasively using a Mini-Motionlogger actimetry device 
(Ambulatory Monitoring Inc., USA) for at least 72 hr. This watch-sized piezoelectric linear accelerometer 
has a memory chip for data storage and continuously records the number of nondominant-wrist 
accelerations per minute.19, 20, 22, 24 Actimetry time series were analyzed using a dedicated program 
(Action 4, version 1.10; Ambulatory Monitoring Inc., USA) to provide a robust, well-characterized and 
clinically meaningful parameter, the dichotomy index (I<O), to estimate individual circadian rest/activity 
pattern.22, 24, 25 This dichotomy index provides an integration of the circadian regulation of sleep and 
activity and represents the percentage of minutes during the rest span when activity is lower than the 
median activity during wakefulness.34 In the case of a robust and marked circadian rest-activity pattern, 
I<O approaches or reaches 100%. The lower the I<O value the more severe the disruption of the circadian 
rest-activity rhythm. Here, we defined circadian disruption during chemotherapy as a value for I<O lower 
than or equal to 97.5%, based on results from a pooled analysis of rest-activity records obtained from 436 
patients with metastatic colorectal cancer in the absence of chemotherapy administration.23 
Clinical outcomes 
Overall incidence of severe or life-threatening toxicity was calculated throughout the treatment span, 
according to the National Cancer Institute Common Toxicity Criteria, version 2.0. The best objective tumor 
response on treatment was evaluated and rated according to the WHO criteria. Overall and progression-
free survival durations were computed from the first day of rest-activity monitoring until the event date or 
the last contact date. The database was updated and locked on November 2007. 
Toxicity assessment 
Clinical and hematological toxicities were assessed at least fortnightly and graded according to the National 
Cancer Institute Common Toxicity Criteria, version 2.0. Patient's weight was measured before each course 
was administered. The toxicity data used here were limited to the worst grade of each type of toxicity 
experienced by the patient during the interval between the beginning of the course preceding and that 
following rest-activity monitoring. 
Hematological (anemia, thrombocytopenia, leucopenia and neutropenia) and clinical toxicities (diarrhea, 
mucositis, hand-foot syndrome, peripheral sensory neuropathy, nausea and vomiting, fatigue and body 
weight loss) were assessed. No data were available for anorexia. Based upon previous reports showing a 
significant association between fatigue or weight loss and altered locomotor activity rhythm before or off 
chemotherapy,3, 22, 24–26 we considered these two events separately from the other toxicities, for which 
no association with circadian dysfunction has been reported to date. Clinical relevance was attributed to 
Grade 2 or 3 fatigue35 or grade 1 body weight loss, corresponding to 5% or more within 2 weeks.36 The 
other toxicities were considered as clinically relevant if they were of Grade 3 or more. 
Statistical analyses 
The main endpoint of this study was to document the clinical impact of circadian disruption during 
chemotherapy on overall survival. First, overall survival curves were compared according to circadian 
disruption (I<O less than or equal to 97.5%) or robustness (I<O greater than 97.5%), using the Kaplan–Meier 
method and the logrank test. Then, Cox multivariate hazard modeling was performed adding sex, 
treatment schedule, number of metastatic sites, rank of chemotherapy course with actimetry and 
Performance Status on day 1 of the course as fixed covariates in order to explore the independent 
prognostic value of circadian disruption during chemotherapy. Secondary aims included the evaluation of 
the impact of circadian disruption on chemotherapy on other clinical outcomes, the documentation of its 
incidence and the identification of its associated clinical features and toxic events. The clinical and 
demographic characteristics considered included age, sex, site of primary tumor, number of metastatic 
sites, performance status (PS) both at trial entry and before actimetry (WHO scale), categorized body mass 
index at study entry, randomized treatment schedule, number of chemotherapy courses given before 
actimetry, the interval in days between actimetry recording and chemotherapy cycle start, as well as the 
corresponding doses of oxaliplatin and 5-fluorouracil. 
Exploratory analyses involved two-sided Fisher's exact test for categorical variables and a Mann-Whitney U 
test for quantitative parameters. The tests enabled comparisons of clinical features or toxic events 
according to I<O values above versus equal to or lower than 97.5%. Multivariate binary logistic regression 
was used in order to identify the clinical features and toxicity events associated with circadian disruption 
during chemotherapy. The assumption of a normal distribution of I<O was tested using the Kolmogorov-
Smirnov test. Missing data for any parameter were not imputed and percentages reported here refer to 
available data for each variable. The threshold for statistical significance was set at 5%. Analyses were 
performed using PASW Statistics 18 software (SPSS Inc., USA). 
Results 
Clinical and demographical characteristics 
Seventy-seven patients fulfilled the inclusion criteria, with locomotor activity being recorded during or 
within the week following the first day of administration of a chemotherapy course. This represented 13.7% 
of the whole population of the patients registered in the Phase III trial and 40.3% of those enrolled at the 
Institutions participating in the companion translational study. The main clinical and demographical 
characteristics and the overall outcomes of the current study patients were similar to those of the whole 
trial population31 (Table 1). 
Table 1. Clinical and demographical characteristics of the 77 patients in the current study, according to the 
presence or absence of circadian disruption during chemotherapy 
 
Timing of actimetry monitoring 
A median of five chemotherapy courses (range, 1 to 9) was given before the current “on treatment” wrist-
actimetry monitoring (Fig. 1a). Recording took place during chemotherapy delivery itself for 80.5% of the 
patients. The median interval between the onset of chemotherapy and that of actimetry was one day (Fig. 
1b). 
 
Figure 1.  
Timing of actimetry in relation to chemotherapy. Panel a: cycle rank following which locomotor activity was 
recorded. Panel b: interval in days between the beginning of the administration of the chemotherapy 
course and the beginning of wrist actimetry. 
I<O distribution 
The distribution of I<O was not normal (p < 0.0001). The respective median and mean values of I<O were 
97.5% (interquartile range, 5.3%) and 95.1% (standard deviation, 7.8%) (Fig. 2). The median I<O value 
corresponded exactly to the cut-off value previously selected for defining circadian disruption. Thus, the 39 
patients with altered circadian rest-activity rhythm (i.e., I<O lower than or equal to 97.5%) represented 
50.6% of the current study population (Table 1; Fig. 2). Patients with circadian disruption displayed a 
median I<O of 93.8% (range: 42.3% to 97.5%), whilst the median I<O value of the patients with a robust 
circadian rest-activity rhythm was 98.9% (range: 97.6% to 100%). Overall, the distribution pattern of I<O on 
treatment strongly resembled that reported at baseline in two independent cohorts involving 130 and 170 
patients with metastatic colorectal cancer patients, respectively.22, 24, 25  
 
Figure 2.  
Distribution of the parameter I<O in the current study population. I<O values ≤ 97.5% define circadian 
disruption and are in the gray area. Each dot represents a patient and the bars represent the median 
(97.5%) with the 1st and 3rd quartiles and the whiskers show the range. 
Circadian disruption during chemotherapy and clinical outcomes 
No statistically significant difference was found for objective response rate (p = 0.82), progression-free 
survival (p = 0.79) and overall Grade 3–4 toxicity rate (p = 0.80) according to I<O value (Table 1). 
Conversely, overall survival was significantly longer in the patients with a robust circadian rhythm as 
compared to those with circadian disruption (p = 0.013) (Fig. 3; Table 1). The negative prognostic value of 
circadian disruption during chemotherapy remained statistically significant after adjustment for sex, 
treatment schedule, number of metastatic sites, rank of chemotherapy course of interest and PS on day1 
according to a Cox model (Table 2) (p = 0.004). Thus, the patients with an altered rest-activity circadian 
rhythm during chemotherapy displayed an independent and doubled risk of an earlier death following rest-
activity monitoring as compared to the patients with a robust circadian rhythm (Hazard Ratio: 2.12; 95% CL: 
1.27–3.54) (Table 2). 
 Figure 3.  
Kaplan–Meier curves depicting overall survival, computed from the beginning of actimetry according to the 
persistence of marked circadian function (black dashed line) or the occurrence of circadian disruption (solid 
gray line). p-Value derived from a logrank test. Hazard ratio derived from a univariate Cox proportional 
hazard model. 
Table 2. Multivariate proportional hazard model for overall survival 
 Circadian disruption and clinical features 
The baseline clinical characteristics of the patients at study entry were similar regardless of the subsequent 
occurrence of circadian disruption on chemotherapy (Table 1). No difference in any feature related to the 
chemotherapy course of interest was observed between patients with circadian disruption and those with a 
robust circadian rhythm (Table 1). The duration of the course of chemotherapy of interest and the related 
rates of cycle delay or dose modifications were similar in the subgroup of patients with circadian disruption 
and that of patients with a robust circadian rhythm (Table 1). Exploratory statistical comparisons between 
patients with altered or robust circadian rest-activity rhythm on chemotherapy showed no statistically 
significant difference according to age (p = 0.48), PS (p = 0.60), BMI (p = 0.65), number of metastatic sites (p 
= 0.48), site of primary tumor (p = 0.49), actual administered dose of oxaliplatin (p = 0.99) or 5-fluorouracil 
(p = 0.93), PS on first day of the treatment course of interest (p = 0.22), course rank (p = 0.46), duration of 
chemotherapy course (p = 0.78), or timing of actimetry in relation to course onset (p = 0.45). The incidence 
of circadian disruption during chemotherapy did not significantly differ according to gender (p = 0.64) or 
treatment schedule (p = 0.71). The highest incidence of circadian disruption was observed in females on 
chronoFLO4 (64.3%) as compared to the other three subgroups (≤50.0%). 
Factors predicting the occurrence of circadian disruption during chemotherapy 
Univariate and multivariate binary logistic regressions failed to identify any clinical or biological parameter 
significantly predicting the occurrence of altered circadian rest-activity rhythm on treatment (p ≥ 0.13; 
details not shown). 
Baseline actimetry was available before the start of chemotherapy for 44 of the 77 patients. Half of them (n 
= 22) had I<O lower than or equal to 97.5%. Baseline circadian disruption did not predict subsequent 
circadian disruption during chemotherapy (p = 0.23; details not shown). Moreover, no significant 
correlation was found between baseline and “on treatment” I<O values (r = 0.15; p = 0.35). 
Toxicity 
Overall, 12 patients (16.0%) experienced Grade ≥ 2 fatigue, and four patients (5.6%) lost 5% or more of 
their body weight, after the chemotherapy course of interest. Both symptoms occurred simultaneously in 
two patients. Grade ≥ 3 clinical or hematological toxicities occurred in 10 patients (13.0%), with each kind 
of toxicity being infrequent (≤ 10.8%, not shown). Thirty-four patients (44.2%) displayed Grade 2–4 clinical 
or hematological toxicities besides fatigue or body weight loss. Performance status worsened in six patients 
(8.2%), and improved in 5 patients (6.8%), following the cycle of actimetry recording (Table 1). The overall 
rate of missing information on toxicity, performance status or body weight was 27/1155 variables (2.3%). 
Circadian disruption and toxicity 
The incidence of circadian disruption during chemotherapy was comparable among the patients whose PS 
deteriorated (50.0%), remained unchanged (46.8%) or improved (60.0%) following the administration of 
the chemotherapy course of interest (p = 0.85). The low incidence of clinically relevant fatigue and body 
weight loss precluded any statistical validation of differences according to I<O values (p = 0.35). However, 
chemotherapy-induced fatigue of Grade 2 or higher occurred twice as often in patients with circadian 
disruption (n = 8; 21.1%) as compared to those with a robust circadian rhythm (n = 4; 10.8%) (Fig. 4). 
Similarly, body weight loss ≥5% occurred three times as frequently in patients with altered rest-activity 
circadian rhythm (n = 3; 8.6%) as compared to those with a robust rhythm (n = 1; 2.7%) (Fig. 4). The 
incidence of other grade ≥3 clinical or hematological toxicities during the chemotherapy course of interest 
was similar in patients with low (n = 5; 12.8%) or high (n = 5; 13.2%) values for I<O (p = 0.96) (Fig. 4). 
Overall, absent or mild toxicities were more frequent in patients with a robust circadian rhythm despite 
chemotherapy as compared to patients with a disrupted circadian rest-activity rhythm (65.8% vs. 46.2%; p 
= 0.11). 
 
Figure 4.  
Incidence of clinically relevant toxicities in the subgroups of patients with robust (white bars) or disrupted 
(gray bars) circadian rest/activity rhythm. 
Discussion 
In this international study, we explored the associations between circadian disruption during chemotherapy 
and treatment-induced adverse events and clinical outcomes. The status of the circadian timing system was 
estimated using noninvasive recording of locomotor activity with a wristwatch actimetry device, and the 
computation of a robust and validated circadian parameter, the dichotomy index (I<O).22, 24, 25, 34 Data 
from a pooled analysis of 436 patients with metastatic colorectal cancer allowed the identification of a cut-
off value of 97.5% for I<O, below which the patients incurred clinically relevant circadian disruption.23 
A transversal design was used to describe and compare the incidence of chemotherapy-induced toxicities 
between patients with robust or altered circadian timing system. By contrast, a repeated measures 
approach has been used by other researchers to explore the dynamics of circadian or sleep functions 
during treatment and their correlations with the temporal evolution of a subjectively rated symptom, 
mainly fatigue.26, 28, 32, 37, 38 These studies have consistently described an inverse correlation between 
the patterns of fatigue and those of physical activity or sleep efficiency over time.26, 28, 32, 37, 38 
Most importantly, our study shows that overall survival is significantly longer in the patients who display a 
robust circadian rest-activity rhythm during chemotherapy, as compared to those with circadian disruption, 
independently from other prognostic factors or experimental conditions. This result complements previous 
studies already documenting the independent prognostic value of baseline I<O for the overall survival of 
patients with metastatic colorectal cancer.22, 24 Also, this finding supports the hypothesis that undue 
chemotherapy-induced circadian disruption could lead to a deterioration in host mechanisms involved in 
cancer control and could shorten overall survival.14 Conversely, an improvement in circadian function 
during chemotherapy could reflect improved host control of tumor growth, with an associated better 
prognosis, as shown experimentally.16 However, the observational nature of the study does not provide 
any definitive evidence on the causal relationship between chemotherapy-induced circadian disruption and 
shorter overall survival. 
This study has also examined the incidence of clinically relevant toxicities occurring during the 
chemotherapy course when circadian rhythm evaluation was performed. Previous studies in experimental 
models and in cancer patients have shown that chemotherapy can disrupt host circadian rhythms.14, 27, 
28, 32 This novel and hitherto overlooked toxicity impacting the circadian timing system could potentially 
hinder the anticancer activity and the safety of cancer chronotherapy, whose foundations assume 
consistent and predictable circadian rhythms in those physiological and molecular parameters which 
mediate pharmacological effects and cancer proliferation.13, 14, 39 Here, the female patients on 
chronoFLO4 displayed the highest rate of chemotherapy-induced circadian disruption (64%) and the worst 
clinical outcomes in the Phase-III trial. Conversely, circadian disruption occurred in 46% of the current male 
patient sample on chronoFLO4, the subgroup which achieved best survival outcome in the same trial.31 
These findings support the hypothesis that sex-related differences in the human circadian timing system 
properties40–42 could result in survival and tolerance disparities on chronotherapy,31, 43 thus implying 
that the optimal chronotherapy schedule might differ between men and women. 
The small sample size and the low incidence of adverse events in our study precluded any statistical 
validation of differences in adverse events according to I<O. However, fatigue and weight loss occurred 
selectively and several times more often in patients with circadian disruption as compared to those with a 
robust circadian rhythm (Fig. 4). These findings concur with those of other studies reporting an association 
between circadian disruption and fatigue, anorexia and weight loss in cancer patients and in healthy 
subjects intolerant to shift work or jet lag.3, 22, 24–26, 44, 45 These symptoms frequently cluster as a 
consequence of the burden of cancer and in association with toxic chemotherapy,3, 46–49 suggesting 
shared underlying patho-physiological mechanisms. The circadian timing system, which temporally 
coordinates the main physiological functions, including physical performance and appetite,3, 13, 14, 39 
could, when disrupted, be one of the main determinants in the pathogenesis of this symptom cluster, thus 
representing a potential treatment target.3 
In our study, baseline circadian pattern did not seem to predict for forthcoming circadian robustness or 
disruption during chemotherapy administration, although the cohort of patients with both baseline and on-
treatment actimetry assessments consisted of only 44 patients, thus preventing any definitive conclusion 
on this issue. Indeed, we observed both improvement and worsening of circadian function during 
chemotherapy, as compared to baseline assessment, in agreement with findings in an independent cohort, 
evaluated with a continuous monitoring approach.33 
Another limitation of the current study is related to the heterogeneity in the timing of actimetry in relation 
to treatment, in terms of course rank and toxicity assessment. However, no difference in the incidence of 
circadian disruption was found with regard to treatment timing (cycle number or days elapsed since onset 
of cycle) (Table 1), supporting the merging of all available data with regard to timing of actimetry. 
Moreover, this transversal approach gives a unique global assessment along the treatment span of the 
clinical and toxic correlates of circadian disruption during chemotherapy. However, whilst actimetry was 
performed for 72 hr during the initial week of the chemotherapy course, the precise timing of occurrence 
of the assessed toxicities was unknown and spanned the whole duration of the treatment course and 
subsequent treatment-free interval. The possible time lag between the occurrence of the toxic event and 
that of chemotherapy-induced circadian disruption was not considered in the current study. This could lead 
to an underestimate of the delved associations found between circadian disruption and toxicity. The 
current results support the future development of prospective and large studies using a continuous and 
repeated measures approach, as currently conducted in a companion translational study to the European 
phase II trial OPTILIV07 (ClinicalTrials.gov Identifier: NCT00852228). 
In this study, we did not explore the possible mechanisms of chemotherapy-induced circadian disruption. 
There is, however, evidence that the release of proinflammatory cytokines following chemotherapy 
administration could account for the occurrence of altered circadian patterns and of systemic symptoms.3, 
6, 10, 11, 48 This hypothesis deserves to be tested in future dedicated studies, since it could provide 
supplemental clues for potential innovative targeted interventional strategies. 
In conclusion, we report here that chemotherapy-induced circadian disruption, as defined according to a 
validated quantitative cut off value for the parameter I<O, is an independent poor prognostic factor for 
overall survival. A value while on chemotherapy of I<O equal to or below this 97.5% predicts a doubled risk 
of earlier death and a 7.6 months reduction in estimated median survival as compared to higher I<O values 
while on chemotherapy (Fig. 3; Table 1). We also show here a higher incidence of clinically relevant fatigue 
and weight loss in patients with altered circadian function during chemotherapy administration. Thus, the 
occurrence of circadian disruption, whether cancer-related or chemotherapy-induced, is consistently 
associated with reduced survival, providing additional evidence for a role of the circadian timing system in 
cancer progression.15–18, 22, 24 The study further provides quantitative estimates that will inform the 
tailored design of prospective studies, which are warranted. Shielding the circadian timing system from 
chemotherapy-induced alterations, through chronotherapy optimization and/or specific pharmacological 
targeting, could become a novel therapeutic objective for simultaneously improving survival and reducing 
systemic symptoms in cancer patients on chemotherapy.14, 24, 50 
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